Akèy › Kansè pankreyas › Washington › Seattle
Etid klinik pou Kansè pankreyas nan Seattle, WA
21 etid pou Kansè pankreyas ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Ap rekriteFaz 3
- University of Washington Fred Hutchinson Cancer Center, Seattle
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Ap rekriteFaz 1
- Swedish Cancer Institute, Seattle
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Fred Hutchinson Cancer Center, Seattle
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Ap rekriteFaz 2/3
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center, Seattle
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Ap rekriteFaz 3
- Fred Hutchison Cancer Center, Seattle
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Ap rekriteFaz 3
- Virginia Mason Franciscan Health - Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center - Advanced Cancer Research Group, Seattle
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Ap rekriteFaz 1/2
- Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Ap rekriteFaz 3
- Investigative Site US032, Seattle
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Ap rekriteFaz 2
- Local Institution - 0086, Seattle
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Ap rekriteEtid obsèvasyon
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Ap rekriteFaz 2
- Virginia Mason, Seattle
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Ap rekriteFaz 1
- Virginia Mason Medical Center, Seattle
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Ap rekriteFaz 3
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- Fred Hutchinson Cancer Center, Seattle
Pancreatic Cancer Early Detection Consortium
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- University of Washington, Seattle
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Fred Hutchinson Cancer Center, Seattle
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Ap rekriteFaz 3
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- ak 3 plis
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Virginia Mason Medical Center, Seattle
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Virginia Mason Medical Center, Seattle
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ap rekriteFaz 2
- Ohio State University-Telemedicine, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Seattle
Etid Kansè pankreyas nan lòt vil
- Houston, TX61 etid
- New York City, NY60 etid
- Boston, MA43 etid
- Nashville, TN39 etid
- Los Angeles, CA35 etid
- St. Louis, MO33 etid
- Arlington, VA33 etid
- San Antonio, TX31 etid
- Baltimore, MD31 etid
- Tampa, FL26 etid
- Philadelphia, PA26 etid
- San Diego, CA24 etid
Lòt etid nan Seattle
- Kansè Poumon ki pa ti selil53 etid
- Kansè (tout kalite)49 etid
- Kansè pwostat42 etid
- Leksemi mieloïd egi40 etid
- Kansè nan tete39 etid
- Kansè Metastatik39 etid
- Kansè kolorektal34 etid
- Kansè poumon33 etid
- Kansè ovè30 etid
- Myelom Miltip22 etid
- Sendwòm myelodisplastik21 etid
- Leksemi limfoblastik egi21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.